Natoli Engineering Company, offers the NP-500 Series, a double-sided, single-footprint rotary tablet press. Designed to compress tablets requiring extra fill and extended dwell time, the NP-500 is a heavy-duty machine with unsurpassed technical support and replacement part availability.
Natoli Engineering Company, Inc. announces the inclusion of the Light Induced Fluorescence (LIF) Sensor in their new Tablet Compression Accessories Catalog. The LIF Sensor was designed for blend uniformity and end-point detection during the blending of powders as well as for liquid applications, including cleaning validation.
Natoli Engineering Company, Inc. announces the inclusion of six industry leading tablet dedusters in their Tablet Compression Accessories Catalog. Spiral-style tablet dedusters, drum-style tablet dedusters, cylinder-shaped tablet dedusters, uphill tablet dedusters, and even combination units are available to suit a variety of needs.
Natoli Engineering Company, Inc. reveals a new, affordable selection of tablet analysis equipment. From balances to laboratoryblenders, and everything in between, there is a variety of analytical equipment to suit a variety of needs.
Exco InTouch, the leading provider of patient engagement, data collection and communication solutions for the pharmaceutical and healthcare sectors, today announced that it has joined the Electronic Patient-Reported Outcome (ePRO) Consortium, a programme run by the Critical Path Institute (C-Path), which strives to enhance the quality of patient reported outcomes (PRO) in the evaluation of new pharmaceuticals.
Aptalis Pharmaceutical Technologies, formerly Eurand Pharmaceutical Technologies, today announced that the European Commission granted marketing authorization for a new pediatric indication of a new oral granule formulation of Gilead Sciences, Inc.'s Viread® (tenofovir disoproxil fumarate) for HIV-1 infected children aged 2 to less than 6 years, and for HIV-1 infected children above 6 years of age for whom a solid dosage form is not appropriate.
Aptalis Pharmaceutical Technologies, formerly Eurand, focused on developing differentiated oral products utilizing its pharmaceutical technologies, today announces its sponsorship of the American Association of Pharmaceutical Scientists (AAPS) Research Achievement Awards in Pharmacokinetics, Pharmacodynamics and Drug Metabolism and its participation in the 2012 AAPS Annual Meeting and Exposition October 14 – 18, 2012 in Chicago, Illinois.
FDA approvals, revenue gain and organic business growth are just a few of the topics that John Fraher, President, Aptalis Pharma, addresses during an on-air interview with Fintan Walton, CEO, PharmaVentures and PharmaTelevision. The interview, conducted during BIO 2012 in Boston, reflects Fraher’s commentary regarding the integration of companies post Axcan Intermediate Holdings’ acquisition of Eurand N.V. in 2011.
Aptalis Pharmaceutical Technologies, a business unit of Aptalis Pharma that focuses on developing differentiated oral products utilizing its pharmaceutical technologies, today announces its co-sponsorship of Controlled Release Society’s Young Investigator Award and its participation in the 39th Annual Meeting & Exposition of the Controlled Release Society July 15 – 18, 2012 in Québec City, Canada.
Aptalis Pharmatech, Inc. (previously known as Eurand, Inc.) and Cephalon, Inc. a wholly-owned subsidiary of Teva Pharmaceuticals Industries Ltd, and Anesta AG prevailed in their appeal to the U.S. Court of Appeals for the Federal Circuit which reversed a lower court’s determination and held that two patents covering the AMRIX® muscle relaxant (Cyclobenzaprine Hydrochloride Extended-Release Capsules) are valid.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.